Equities research analysts expect GlaxoSmithKline plc (NYSE:GSK) to report $0.78 earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for GlaxoSmithKline’s earnings. GlaxoSmithKline posted earnings per share of $0.70 during the same quarter last year, which would suggest a positive year over year growth rate of 11.4%. The company is expected to issue its next earnings results on Wednesday, July 25th.
According to Zacks, analysts expect that GlaxoSmithKline will report full-year earnings of $2.84 per share for the current year, with EPS estimates ranging from $2.73 to $3.05. For the next year, analysts forecast that the company will report earnings of $2.98 per share, with EPS estimates ranging from $2.87 to $3.22. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover GlaxoSmithKline.
GlaxoSmithKline (NYSE:GSK) last posted its earnings results on Wednesday, April 25th. The pharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.02). GlaxoSmithKline had a net margin of 3.50% and a return on equity of 144.84%. The company had revenue of $10.04 billion during the quarter, compared to analyst estimates of $10.26 billion.
GSK has been the subject of a number of recent research reports. Cowen reiterated a “hold” rating and issued a $40.00 target price on shares of GlaxoSmithKline in a research note on Thursday, February 15th. Zacks Investment Research lowered GlaxoSmithKline from a “hold” rating to a “sell” rating in a research note on Wednesday, February 21st. Morgan Stanley upgraded GlaxoSmithKline from an “underweight” rating to an “equal weight” rating in a research note on Thursday, March 22nd. Deutsche Bank reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note on Wednesday, March 28th. Finally, BNP Paribas upgraded GlaxoSmithKline from a “neutral” rating to an “outperform” rating in a research note on Wednesday, April 4th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $40.21.
A number of institutional investors and hedge funds have recently modified their holdings of GSK. We Are One Seven LLC boosted its holdings in GlaxoSmithKline by 185.1% in the first quarter. We Are One Seven LLC now owns 2,677 shares of the pharmaceutical company’s stock valued at $105,000 after purchasing an additional 1,738 shares during the last quarter. Adviser Investments LLC bought a new position in GlaxoSmithKline during the 1st quarter worth approximately $117,000. Toronto Dominion Bank lifted its holdings in GlaxoSmithKline by 133.3% during the 1st quarter. Toronto Dominion Bank now owns 3,150 shares of the pharmaceutical company’s stock worth $123,000 after buying an additional 1,800 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in GlaxoSmithKline during the 1st quarter worth approximately $135,000. Finally, Wealthcare Advisory Partners LLC lifted its holdings in GlaxoSmithKline by 80.8% during the 1st quarter. Wealthcare Advisory Partners LLC now owns 3,570 shares of the pharmaceutical company’s stock worth $139,000 after buying an additional 1,595 shares during the last quarter. 11.09% of the stock is owned by hedge funds and other institutional investors.
Shares of GSK stock traded up $0.80 during trading hours on Friday, reaching $41.94. The company had a trading volume of 3,496,218 shares, compared to its average volume of 3,474,794. The company has a debt-to-equity ratio of 3.90, a quick ratio of 0.40 and a current ratio of 0.61. GlaxoSmithKline has a twelve month low of $34.52 and a twelve month high of $44.44. The firm has a market cap of $102.13 billion, a P/E ratio of 14.56, a price-to-earnings-growth ratio of 2.20 and a beta of 0.83.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 12th. Investors of record on Friday, May 11th will be issued a $0.5298 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 5.05%. The ex-dividend date of this dividend is Thursday, May 10th. GlaxoSmithKline’s dividend payout ratio is currently 72.92%.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.